Indivior Q2 2026 revenue rises 14% and full-year 2026 guidance is raised
Indivior reported second-quarter 2026 total net revenue of $343 million, up 14% year over year, and GAAP net income of $122 million, compared with $18 million a year earlier, and raised its full-year 2026 guidance. The company also announced a definitive agreement for an all-stock merger of equals with Supernus Pharmaceuticals, which it expects to close in the fourth quarter, so shareholders face both the improved outlook and the pending deal's terms and risks.
Key points
- Q2 2026 total net revenue was $343 million, up from $302 million; total SUBLOCADE net revenue was $253 million, up 21%.
- GAAP net income was $122 million ($0.98 diluted EPS) versus $18 million ($0.14 diluted EPS) in Q2 2025.
- Full-year 2026 adjusted EBITDA guidance was raised to $700 million to $740 million from $620 million to $660 million; net revenue guidance was raised to $1,295 million to $1,365 million from $1,215 million to $1,285 million.
- In Q2 2026 the company repurchased 4,664,540 shares for $175 million; the Supernus merger is expected to close in the fourth quarter.
The filing
Written by AI on Nov 8, 2026, 2:07 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.